Clinical Laserthermia Systems AB (publ) announced that their US subsidiary CLS Americas has signed an agreement with ROSE Urology, LLC, in Florida, the US, that will use TRANBERG Thermal Therapy system for treatment of prostate cancer patients. Under CLS's Mobile Services Provider, CLS provides its FDA 510(k) cleared TRANBERG Thermal Therapy System with consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during treatment of prostate cancer patients.
Clinical Laserthermia Systems AB
Equities
CLS B
SE0022049920
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 SEK | +3.58% | -6.32% | -49.28% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-49.28% | 10.26M | |
+2.77% | 872M | |
-18.63% | 257M | |
-31.35% | 80.91M |
- Stock Market
- Equities
- CLS B Stock
- News Clinical Laserthermia Systems AB
- Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System